Business & Economy · 37 views
Insilico Medicine, SK Biopharmaceuticals strike $2.5B AI drug discovery deal targeting neuroimmune therapies
“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine, tells Fortune.
AI Summary
Insilico Medicine and SK Biopharmaceuticals have formed a significant partnership in the field of artificial intelligence-driven drug discovery. This collaboration aims to develop neuroimmune therapies, a promising area of research with potential applications in treating various neurological disorders.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Business & Economy
Continue reading recent Business & Economy coverage
- Neocloud stocks fall as Elon Musk says more than 200 of them face 'guppy-level death'Continue reading
- AI helped me automate some of my wealth advisor job. Here's why I'm not worried about it stealing my edge.Continue reading
- PepsiCo started losing the cola wars when its CEOs lost focusContinue reading
- Tennis star Taylor Fritz is selling his condo for $860,000—with sweeping views of MiamiContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow